QLS‑111 is a novel topical formulation using Qlaris Bio’s ATP-sensitive potassium channel modulator platform. QLS-111 lowers ...

Himani Goyal, MD, takes glaucoma care to the next level by embracing advancements that extend beyond traditional treatment ...

Patients with varying stages of glaucoma saw no significant difference in outcomes between standard and enhanced monofocal ...

Both glaucoma and cancer of the eye may lead to temporary or permanent vision loss, among other vision-related challenges. Early stages of open-angle glaucoma may not cause evident symptoms.

We present a case of unilateral, secondary open-angle glaucoma due to an underlying diffuse iris melanoma. The patient was referred by his ophthalmologist with uncontrolled, elevated intraocular ...

Among patients with suspected or confirmed glaucoma, higher average blood pressure and greater variability in blood pressure ...

New study challenges conventional wisdom about cholesterol! High levels of 'good cholesterol' may increase the risk of ...

Qlaris Bio is seeing double when it comes to phase 2 wins for its eye drug, hitting the primary endpoints in trials that both spanned primary open angle glaucoma (POAG) and ocular hypertension (OHT).

US clinical-stage biotech Qlaris Bio has announced positive top-line results from two U.S. Phase II clinical trials ...

Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced positive topline results from two U.S. Phase II clinical trials ...

Patients with primary open-angle glaucoma or ocular hypertension who ... KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2025, I. Paul Singh, MD, explains excimer laser ...

Touting its novel approach for treating glaucoma, Qlaris Bio Inc. reported promising top-line data from two phase II studies testing QLS-111 in patients with primary open-angle glaucoma and ocular ...